Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Medical Countermeasures

    NIH Projects Advance Treatment for Acute Radiation Syndrome, TBI

    By Global Biodefense StaffDecember 17, 2013
    Share
    Facebook LinkedIn Reddit Email

    The National Institutes of Health today has launched three pre-clinical projects to advance potential new treatments for acute radiation syndrome, brain injury following cardiac arrest and a rare blood disorder called beta thalassemia. The projects are part of the Bridging Interventional Development Gaps (BrIDGs) program, which is funded by the NIH Common Fund and led by NIH’s National Center for Advancing Translational Sciences (NCATS).

    BrIDGs provides eligible scientists with no-cost access to contractor services, such as toxicology studies, for pre-clinical therapeutic development. To be eligible for the program, projects must have been effective in a disease model. Researchers often apply to BrIDGs because they have hit a roadblock and need additional expertise or lack other resources. Rather than funding successful applicants directly, BrIDGs supports expert NIH contractors who perform pre-clinical services for the researchers free-of-charge.

    “BrIDGs researchers and partner scientists work together to bridge the gap between a basic discovery and clinical testing, thereby ensuring potential treatments have a chance to reach patients who need them,” said Christopher P. Austin, M.D., NCATS director.  

    A primary goal of a BrIDGs project is the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration to begin human clinical trials. To date, BrIDGs scientists have generated data to support 12 INDs submitted to the FDA, as well as one clinical trial application to Health Canada. They also have evaluated 12 of the 13 projects in clinical trials. Three BrIDGs-supported therapeutic agents have gone as far as Phase II clinical trials, in which researchers provide an experimental therapy to a group of patients to evaluate its safety and effectiveness. Third-party investors have licensed seven compounds during or after their development through the BrIDGs program. 

    BrIDGs scientists selected the following new projects from the 2013 application solicitation:

    Acute Radiation Syndrome
    Manufacturing of RLIP76-LyoPL for Acute Radiation Syndrome
    Henry Hebel, M.B.A., vice president of drug development
    Terapio Corp., Austin, Texas

    Exposure to radiation, whether from a compromised nuclear reactor or a radiation weapon, can lead to acute radiation syndrome, a life-threatening multi-organ illness. Currently, there is no FDA-approved treatment for the syndrome. This project is designed to develop a treatment that can be administered beginning 24 hours or longer after radiation exposure. NIH’s National Institute of Allergy and Infectious Diseases is co-funding the pre-clinical studies for this project through its Radiation Nuclear Countermeasures Program.

    Beta Thalassemia 
    The Development of Minihepcidins for the Treatment of Beta Thalassemia 
    Brian MacDonald, Ph.D., president and CEO
    Merganser Biotech LLC, Newtown Square, Pa.

    Patients with beta thalassemia, a rare inherited blood disorder, suffer from severe anemia and iron overload that can damage the heart. The disorder reduces production of hepcidin, the iron regulatory hormone. The goal of this project is to develop a treatment that increases levels of hepcidin and lowers the damaging effects of too much iron. NIH’s National Institute of Diabetes and Digestive and Kidney Diseases is co-funding this project.

    Cardiac Arrest-Induced Acute Brain Injury
    HBN-1 Regulated Hypothermia Formulation and Evaluation of Toxicity
    Laurence Katz, M.D., associate professor of emergency medicine
    University of North Carolina at Chapel Hill

    Patients resuscitated from cardiac arrest can suffer from acute brain injury. Lowering a patient’s body temperature into therapeutic-induced hypothermia can improve survival with good neurological outcomes in more than half of patients who remain in a coma after cardiac arrest. This project is designed to develop HBN-1 as an intravenous treatment that paramedics can give to cardiac arrest patients to induce hypothermia sooner. The NIH Common Fund is funding the pre-clinical studies for this project.

    “Although each project is selected for its scientific merit, not all projects will lead to treatments because the pre-clinical phase of drug development is fraught with failures related to issues such as adverse side effects,” said John McKew, Ph.D., acting director of NCATS’ Division of Pre-clinical Innovation and chief of the Therapeutics Development Branch. “Still, the support that BrIDGs provides gives each project a fighting chance.”

    Source: NIH

    NIH Radiation
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleRFP: Phase I Clinical Trial Unit for Infectious Disease Therapeutics
    Next Article FDA Puts Anthrax Vaccine on Clinical Hold Again

    Related Stories

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023

    Mount Sinai to Lead Development of Pan-Coronavirus Vaccine Under New Federal Grant

    September 17, 2023

    Smallpox Vaccines: Bavarian Nordic Awarded Another Contract to Supply EU Strategic Reserve

    September 13, 2023

    HHS Extends Partnership with Regeneron to Develop Life-Saving Monoclonal Antibodies

    September 8, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy